Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in hig
- PDF / 595,554 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 57 Downloads / 125 Views
ORIGINAL ARTICLE
Randomized controlled trial of landiolol, a short‑acting beta‑1 adrenergic receptor blocker, illustrating changes in high‑molecular weight adiponectin levels after elective percutaneous coronary intervention Masayoshi Kiyokuni1 · Masaaki Konishi1 · Yusuke Saigusa2 · Kiwamu Iwata1 · Naoki Nakayama3 · Naohiro Komura1 · Teruyasu Sugano1 · Tomoaki Ishigami1 · Toshiyuki Ishikawa1 · Takeharu Yamanaka2 · Kouichi Tamura1 · Kazuo Kimura1 Received: 6 February 2020 / Accepted: 29 May 2020 © Springer Japan KK, part of Springer Nature 2020
Abstract Adiponectin (APN) has cardioprotective properties and bisoprolol has been reported to increase myocardial APN expression and reduce myocardial damage. Administration of landiolol, which has a higher cardio-selectivity and shorter half-life than bisoprolol, during the percutaneous coronary intervention (PCI) may increase serum APN and high-molecular weight (HMW)-APN, an active form of APN, in patients with stable angina pectoris (SAP). We recruited 70 patients with SAP and randomized them to intravenous landiolol during PCI (N = 35) or control group (N = 35). The primary endpoint was serum APN and HMW-APN level 3 days after PCI. There was no difference in the primary endpoint between the landiolol and control groups (8.93 ± 5.24 vs. 10.18 ± 5.81 μg/mL, p = 0.35 and 3.36 ± 2.75 vs. 4.28 ± 3.13 μg/mL, p = 0.20) for APN and HMW-APN levels, respectively. APN and HMW-APN level were significantly decreased 1 day after PCI [−0.55 ± 0.92 μg/ mL (9.87–9.32 μg/mL), p
Data Loading...
